Floatz logo

BUSULFANUM

Hematopoietic And Lymphoid System Neoplasm

National Cancer Institute (NCI)Small moleculePhase 2Active
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
73/ 100

Competitive context

133 Active assets in the Hematopoietic And Lymphoid System Neoplasm cohort.

Asset / SponsorPhaseRating
Adriamycin
OHSU Knight Cancer Institute
Phase 4BBB
Dexasone
City of Hope Medical Center
Phase 3BB
Teclistamab
Janssen Pharmaceutical K.K.
Phase 2BB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 3BB
Bortezomib
OHSU Knight Cancer Institute
Phase 4BB

View all 50 →

Same molecule, other indications

BUSULFANUM is also rated in:

myelodysplastic/myeloproliferative neoplasmActive
BBB
Indicative · Phase 2/3
76 / 100
View asset →
graft versus host diseaseActive
BBB
Indicative · Phase 4
74 / 100
View asset →
disease related to hematopoietic stem cell transplantActive
BBB
Indicative · Phase 3
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →